MEDIAN Technologies SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0011049824
EUR
3.17
0.07 (2.26%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About MEDIAN Technologies SA stock-summary
stock-summary
MEDIAN Technologies SA
Pharmaceuticals & Biotechnology
Median Technologies SA is a France-based company that publishes software for the diagnosis and monitoring of cancer patients. The Company develops lesion management solutions (LMS) to objectively measure and track cancerous or suspicious lesions, distribute a standardized oncologic report and centralize the lesion information for multidisciplinary review. The LMS line includes such products as LMS-Lung, a clinical application for the detection, evaluation and follow-up of lesions identified in CT images covering the chest; LMS-Track, a clinical application for the follow-up of oncology patients; and LMS-Liver, a clinical application for the initial evaluation and the follow-up of liver metastases and any other lesions identified in CT images covering the liver. The Company operates one subsidiary, Median Technologies Inc, based in the United States.
Company Coordinates stock-summary
Company Details
Les Deux Arcs B, 1800 route des Cretes , VALBONNE None : 06560
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.18%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Oran Muduroglu
Chairman of the Board
Ms. Jeanne Hecht
Chief Operating Officer, Director
Mr. Gerard Milhiet
Executive Vice President, Director
Dr. Kapil Dhingra
Director
Mr. Timothy Haines
Director
Dr. Otello Stampacchia
Director
Oren Stuge
Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 120 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.82

stock-summary
Return on Equity

56.66%

stock-summary
Price to Book

-2.95